The incidence of acute pancreatitis with GLP-1 receptor agonist therapy in individuals with a known history of pancreatitis

Laura D Lomeli; Alimitha M Kodali; Yumiko Tsushima; Adi E Mehta; Kevin M Pantalone

doi:10.1016/j.diabres.2024.111806

The incidence of acute pancreatitis with GLP-1 receptor agonist therapy in individuals with a known history of pancreatitis

Diabetes Res Clin Pract. 2024 Sep:215:111806. doi: 10.1016/j.diabres.2024.111806. Epub 2024 Aug 5.

Authors

Laura D Lomeli¹, Alimitha M Kodali², Yumiko Tsushima³, Adi E Mehta⁴, Kevin M Pantalone⁵

Affiliations

¹ Department of Endocrinology, Cleveland Clinic, Cleveland, OH, USA. Electronic address: [email protected].
² Carolina Health Specialist, Myrtle Beach, SC, USA. Electronic address: [email protected].
³ University Hospitals, Cleveland, OH, USA. Electronic address: [email protected].
⁴ Department of Endocrinology, Cleveland Clinic, Cleveland, OH, USA. Electronic address: [email protected].
⁵ Department of Endocrinology, Cleveland Clinic, Cleveland, OH, USA. Electronic address: [email protected].

PMID: 39111552
DOI: 10.1016/j.diabres.2024.111806

Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1RA) have been reported to increase the risk of acute pancreatitis (AP). This real-world study did not observe a higher frequency of AP with GLP-1RA exposure in adults with T2D and a prior history of AP regardless of etiology.

Keywords: Drug adverse reactions; GLP-1RA; Pancreatitis; Type 2 diabetes.

MeSH terms

Acute Disease
Adult
Aged
Diabetes Mellitus, Type 2* / drug therapy
Diabetes Mellitus, Type 2* / epidemiology
Female
Glucagon-Like Peptide-1 Receptor* / agonists
Humans
Hypoglycemic Agents / adverse effects
Hypoglycemic Agents / therapeutic use
Incidence
Male
Middle Aged
Pancreatitis* / chemically induced
Pancreatitis* / epidemiology

Substances

Glucagon-Like Peptide-1 Receptor
Hypoglycemic Agents